Pacira BioSciences competitors

• Pharmaceutical/Biotech executive with over 23 years’ experience in successful commercialization (sales, marketing, trade, managed markets, training and development, market research, sales operations, supply chain), general operations (IT, facilities), business development, leadership development, investor relations and strategic planning. • Proven track record of commercialization success in diverse business structures including large public pharma, start-up specialty private pharma and public biotech inclusive of building and scaling commercial operations to the needs of the organization. • Accomplishments include launching a blockbuster mass market brand/category, re-launching specialty and mass market brands to generate positive brand P&Ls, and corporate M&A leading to the exit of a specialty pharma company for $1.65B.

Milind Deshpande is a President and Chief Executive Officer at ACHILLION PHARMACEUTICALS INC and is based in United States.

As part of the executive team, responsible for building a sustainable profitable business unit for Merck in the new rapidly growing biosimilar space and to become a recognized and respected global player. Accountable for: building and leading a high performance global talented team; developing new ideas for commercialization; nurturing a 'start up’ entrepreneurial environment and a 'different than Rx' mindset; delivering on strategic and financial goals for the unit; and most importantly playing a significant role in driving a step change in the healthcare paradigm by driving greater affordability and access to important quality biologics for patients around the world.

James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Stephan Kutzer is a Chief Executive Officer at CAMBRIDGE MAJOR LABORATORIES and Chief Executive Officer at AAIPharma Services. He has worked as COO:Pharma & Biotech Mkt Segment at Lonza America Inc., Head:Performance Chemicals at Lonza America Inc., and Assistant Production Manager at Lonza America Inc.. Stephan attended Technical University of Munich.